Tupperware Fundamentals Deemed Solid and 4 Stock Analyses Attracting Attention

Hub Group Inc. (NASDAQ:HUBG): Current price $36.48

After Hub Group Inc. reported higher than expected fourth quarter earnings per share, RBC Capital remains upbeat on the stock and raised their target on the shares from $36 to $43 while maintaining an Outperform rating.

hubg

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Tupperware Brands Corporation (NYSE:TUP): Current price $74.73

After Tupperware Brands Corporation reported higher than expected fourth quarter earnings per share, RBC Capital increased their price target on the stock as the firm thinks that the company’s fundamentals are solid and that they can continue to generate best in class EPS and sales growth. They maintain an Outperform rating on the shares.

tup

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Current price $20.07

RBC Capital believes that several upcoming events could enable Ariad Pharmaceuticals Inc.’s stock to advance significantly more than bears expect. Such events include stronger than expected sales of the company’s Iclusig drug and positive clinical results for their 113 lung cancer drug. The firm keeps a $28 price target and Outperform rating on the shares.

aria

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Mastercard Incorporated (NYSE:MA): Current price $517.19

Given European weakness, moderating United States spending growth, and higher than expected rebates, UBS expects MasterCard Incorporated to report a fourth quarter revenue of $1.879 billion vs. consensus of $1.891 billion. The firm reiterates their Sell rating and believes valuation remains rich and raised their price target from $4.12 to $425.

ma

Theravance Inc. (NASDAQ:THRX): Current price $22.20

Piper Jaffray believes the positive Federal Drug Administration panel recommendation for Boehringer’s Olodaterol in COPD signals a similar outcome for Theravance’s Breo’s panel on March 7. The firm recommends buying shares of Theravance Inc. ahead of the FDA panel and keeps an Overweight rating on the name with a $32 price target.

thrx